Nicolas Provost

Gif-sur-yvette, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 13 publications

ABHD6 suppression attenuates pro-inflammatory responses in mice and promotes anti-inflammatory polarization of macrophages during endotoxin stress.

ABHD6 suppression attenuates pro-inflammatory responses in mice and promotes anti-inflammatory polarization of macrophages during endotoxin stress.

Journal: Biochimica et biophysica acta. Molecular and cell biology of lipids

Published: May 11, 2025

Asparagine synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinoma.

Asparagine synthetase promoter hypermethylation is required, but not sufficient, for sensitivity to Asparlas in patient-derived models of hepatocellular carcinoma.

Journal: European journal of pharmacology

Published: March 12, 2025

Glucose deprivation and identification of TXNIP as an immunometabolic modulator of T cell activation in cancer.

Glucose deprivation and identification of TXNIP as an immunometabolic modulator of T cell activation in cancer.

Journal: Frontiers in immunology

Published: December 19, 2024

Covalent Inhibitors of KEAP1 with Exquisite Selectivity.

Covalent Inhibitors of KEAP1 with Exquisite Selectivity.

Journal: Journal of medicinal chemistry

Published: November 21, 2024

Characterization of CD4+ and CD8+ T cells responses in the mixed lymphocyte reaction by flow cytometry and single cell RNA sequencing.

Characterization of CD4+ and CD8+ T cells responses in the mixed lymphocyte reaction by flow cytometry and single cell RNA sequencing.

Journal: Frontiers in immunology

Published: October 12, 2023

A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease.

A new NRF2 activator for the treatment of human metabolic dysfunction-associated fatty liver disease.

Journal: JHEP reports : innovation in hepatology

Published: December 29, 2022

Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis.

Antibody-mediated neutralization of galectin-3 as a strategy for the treatment of systemic sclerosis.

Journal: Nature communications

Published: October 28, 2022

Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice.

Selective disruption of NRF2-KEAP1 interaction leads to NASH resolution and reduction of liver fibrosis in mice.

Journal: JHEP reports : innovation in hepatology

Published: June 01, 2022

Addressing the quality challenge of a human biospecimen biobank through the creation of a quality management system.

Addressing the quality challenge of a human biospecimen biobank through the creation of a quality management system.

Journal: PloS one

Published: May 04, 2022

Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression.

Procollagen C-Proteinase Enhancer-1 (PCPE-1) deficiency in mice reduces liver fibrosis but not NASH progression.

Journal: PloS one

Published: August 05, 2021

Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs.

Characterization and Pharmacological Validation of a Preclinical Model of NASH in Göttingen Minipigs.

Journal: Journal of clinical and experimental hepatology

Published: July 07, 2021

MG53 is not a critical regulator of insulin signaling pathway in skeletal muscle.

MG53 is not a critical regulator of insulin signaling pathway in skeletal muscle.

Journal: PloS one

Published: November 25, 2020

Showing 1-12 of 13

Last Updated: 09/26/2026